Abbott Diabetes Care has recalled some of its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitor sensors for people ...

This is now a Class I recall, meaning that the use of these continuous glucose monitoring systems could cause serious health ...

Abbott Laboratories (ABT) stock is down as the FDA classifies the company's recent recall of FreeStyle Libre 3 glucose ...

The Food and Drug Administration (FDA) has now identified the recall of certain FreeStyle Libre glucose monitor sensors as “most serious" and is warning that using the recalled device may cause ...

FreeStyle Libre 3 and 3 Plus are continuous glucose monitoring devices indicated for the management of diabetes in patients aged 4 years and older.

Abbott has been hit with a slew of complaints from the FDA in a warning letter related to its continuous glucose monitor (CGM ...

Add Yahoo as a preferred source to see more of our stories on Google. A subset of FreeStyle Libre 3 plus sensors may provide incorrect low glucose reading, Health Canada says. (Brian Morris/CBC - ...

Boone Health said Abbott has been assisting with the redistribution of new monitors Freestyle Libre 3 and 3 Plus since recall.

Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.

Abbott has secured a European approval for the newest generation of its FreeStyle Libre continuous glucose monitor—which the company describes as the world’s smallest and thinnest diabetes sensor, ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...